Wednesday, Madrigal Pharmaceuticals, Inc. (MDGL) announced its first-quarter financial results, reporting a net loss of $94.4 million, or $3.25 a share, compared to $73.2 million, or $2.61 a share, in the previous year. Total operating expenses increased to $404.1 million from $216.6 million in the...
Stock of Madrigal Pharmaceuticals, Inc. (MDGL) is falling about 11 percent on Thursday morning trading despite reporting positive fourth quarter financial results, which saw a drop in net loss to $58.58 million, or $2.57 per share, from $59.42 million, or $2.71 per share, last year. The company's...
Madrigal Pharmaceuticals, Inc. (MDGL) announced Loss for fourth quarter of -$58.58 million The company's bottom line totaled -$58.58 million, or -$2.57 per share. This compares with -$59.42 million, or -$2.71 per share, last year. The company's revenue for the period rose 210.8% to $321.08 million...
Madrigal Pharmaceuticals, Inc. (MDGL) announced that the United States Patent and Trademark Office has issued a Notice of Allowance covering the FDA-approved use of Rezdiffra or resmetirom, the first and only FDA-approved treatment for adults with noncirrhotic MASH with moderate to advanced liver fibrosis....
Madrigal Pharmaceuticals, Inc. (MDGL) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of resmetirom, or Rezdiffra, for the treatment of adults with noncirrhotic MASH with moderate to advanced liver...
August 13, 2026 05:33 ET The World Health Organization’s cancer research agency, the International Agency for Research on Cancer (IARC), has classified three widely used medicines as carcinogenic to humans.